AAMU
FPRX

Amundi Asset Management US’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Amundi Asset Management US’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-202,800
Closed -$3.48M – 1643
2018
Q1 		$3.48M Hold
202,800
– – 0.01% 948
2017
Q4 		$4.45M Buy
+202,800
New +$6.52M 0.01% 864

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Amundi Asset Management US's FPRX Position: Q2 2018 in Review

Amundi Asset Management US sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2018, closing a stake of 202,800 shares — an estimated $3.48M sold.

Amundi Asset Management US first reported a position in FPRX in Q4 2017 and held it in 2 quarters. The position peaked at $4.45M in Q4 2017. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2018.

  • Amundi Asset Management US reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 202,800 Five Prime Therapeutics, Inc. shares in Q2 2018, an estimated $3.48M.
  • Amundi Asset Management US first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Amundi Asset Management US's Five Prime Therapeutics, Inc. position peaked at $4.45M in Q4 2017.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2018.

Based on Amundi Asset Management US's 13F filing for Q2 2018, filed 13 Aug 2018.